Roivant said brepocitinib, which is under priority FDA review for dermatomyositis, is expected to launch by the end of September if it receives approval. Roivant expects top-line data from that study in 2028. Roivant also said its registrational study of brepocitinib in lichen planopilaris is enrolling “extremely well,” according to Gline. He said the company expects to be the first to bring an advanced therapy to the market if its program succeeds. About Roivant Sciences (NASDAQ:ROIV)Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.”